RxDoctor Payments Data

Gener Cruz

Adult Health · Las Vegas, NVNPI 1811612310

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 170 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 35.0% of the total. 2025 is the largest year on record at $1,711, more than ten times the $91 reported in 2023.

$3,365in general payments, 2019–2025

Across 170 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$524
  • Johnson & Johnson$280
  • Sanofi$244
  • Phathom Pharmaceuticals, Inc.$187
  • Takeda Pharmaceuticals U.S.A., Inc.$129
  • plus $822 from 14 others

What the payments were for

  • Food & beverage$3,365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,365 in reported general payments places this provider in the 80th percentile of 90 adult health providers in Nevada.

See all adult health providers in Nevada

Medicare billing

Part B allowed, 2024
$78,255
Medicare patients
599
Services billed
780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$89,185
LinzessLinaclotide24$15,982
ClenpiqSod Picosulf/Mag Ox/Citric Ac18$3,047
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag19$2,362
Famotidine224$2,046
Mesalamine16$1,410
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates17$1,075
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl52$762
Dicyclomine Hcl48$545
Pantoprazole Sodium83$538
Esomeprazole Magnesium13$491
Omeprazole28$214
Hydrocortisone14$144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,179$15,98224 claims
Braintree Laboratories, Inc.Suflave$74$2,36219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 90 adult health providers in Nevada.

Other adult health in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →